Surviving the first hours in sepsis: Getting the basics right (an intensivist's perspective)

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue SUPPL. 2, 2011, Pages

  Daniels, Ron ^a  

^a HOPE HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Bundles; Critical; Cultures; Lactate

Indexed keywords

BIOLOGICAL MARKER; LACTIC ACID;

ARTICLE; DISEASE SEVERITY; GENE EXPRESSION PROFILING; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE; LACTATE BLOOD LEVEL; MEDICAL SPECIALIST; MICROARRAY ANALYSIS; MORBIDITY; MORTALITY; NURSE; RELIABILITY; RESUSCITATION; RISK ASSESSMENT; SEPSIS; SURVIVAL; UNITED KINGDOM;

CLINICAL LABORATORY TECHNIQUES; CRITICAL ILLNESS; GREAT BRITAIN; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEPSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79952591073     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq515     Document Type: Article

References (119)

1. Davies A, Green C, Hutton J. Severe sepsis: a European estimate of the burden of disease in ICU. Int Care Med 2001; 27: S284.
2. Karlsson S, Varpula M, Ruokonen E. Incidence, treatment and outcome of severe sepsis in ICU-treated adults in Finland - the Finnsepsis Study. Int Care Med 2007; 33: 435-43.
3. Blanco J, Muriel-Bombin A, Sagredo V et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multi-centre study. Crit Care 2008; 12: R158.
4. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
5. Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
6. The Intensive Care National Audit and Research Centre: Case Mix Programme Database (interrogated January 2006). http://www.icnarc.org (5 May 2010, date last accessed).
7. Gao F, Melody T, Daniels DF et al. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care 2005; 9: R764-70.
8. Sands KE, Bates DW, Lanken PN et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-40.
9. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997; 25: 1095-100.
10. Vincent JL, Sakr Y, Sprung CL et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
11. Levy MM, Dellinger RP, Townsend SR et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement programtargeting severe sepsis. Crit Care Med 2010; 38: 1-8.
12. The Barcelona Declaration of the Surviving Sepsis Campaign. http://www.survivingsepsis.org/Background/Pages/barcelona_declaration.aspx (5 January 2011, date last accessed).
13. Dellinger RP, Carlet JM, Masur H et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-73.
14. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Special Article. Crit Care Med 2008; 36: 296-327.
15. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis-practice guidelines, marketing campaigns, and Eli Lilly. NEJM 2006; 355: 1640-2.
16. Heyworth J, Keep J, Daniels R on behalf of the Clinical Effectiveness Committee of the College of Emergency Medicine. Sepsis pack 2009. http://www.collemergencymed.ac.uk (5 May 2010, date last accessed).
17. Simmonds M, Hutchinson A, Chikhani M et al. Surviving sepsis beyond intensive care: a retrospective cohort study of compliance with the international guidelines. J Int Care Soc 2008; 9: 124-7.
18. Sivayoham N. Management of severe sepsis and septic shock in the emergency department: a survey of current practice in emergency departments in England. Emerg Med J 2007; 24: 422.
19. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Int Care Med 2003; 29: 530-8.
20. Carlbom DJ, Rubenfeld GD. Barriers to implementing protocol-based sepsis resuscitation in the emergency department-results of a national survey. Crit Care Med 2007; 35: 25-32.
21. Survive Sepsis education programme. www.survivesepsis.org (5 May 2010, date last accessed).
22. Trzeciak S, Chansky ME, Dellinger PR et al. Operationalizing the use of serum lactate measurement for identifying high risk of death in a clinical practice algorithm for suspected severe sepsis. Acad Emerg Med 2006; 13: 150-1.
23. Drumheller B, Goyal M, Pines J et al. Elevated point-of-care lactate at triage is predictive of admission among sepsis patients presenting to the emergency department. Ann Emerg Med 2007; 50: S21-2.
24. Chan Y-L, Tseng C-P, Tsay P-K et al. Procalcitonin as a marker of bacterial infection in the emergency department: an observational study. Crit Care 2004; 8: R12-20.
25. Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. Shock 2008; 29: 328-33.
26. Billeter A, Turina M, Seifert B et al. Early serum procalcitonin, interleukin-6, and 24-hour lactate clearance: useful indicators of septic infections in severely traumatized patients. World J Surg 2009; 33: 558-66.
27. Nguyen HB, Rivers EP, Knoblich BP et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004; 32: 1637-42.
28. Hanudel P, Wilcox S, Cadin E et al. Prevalence of cryptic shock in a cohort of out-of-hospital sepsis patients: an argument for prehospital point-of-care lactate. Ann Emerg Med 2008; 51: 487-8.
29. Weinstein MP, Reller RB, Murphy JR et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 1983; 5: 35-53.
30. Cockerill FR, Wilson JW, Vetter EA et al. Optimal testing parameters for blood cultures. Clin Infect Dis 2004; 38: 1724-30.
31. Lee A, Mirrett S, Reller L et al. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol 2007; 45: 3546-8.
32. Blot F, Schmidt E, Nitenberg G et al. Earlier positivity of central venous versus peripheral blood cultures is highly predictive of catheter-related sepsis. J Clin Microbiol 1998; 36: 105-9.
33. Alvarez-Lerma F. Modification of empiric treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Int Care Med 1996; 22: 387-94.
34. Hoffken G, Niederman MS. Nosocomial pneumonia: the importance of a de-escalation strategy for antibiotic treatment of pneumonia in the ICU. Chest 2002; 122: 2183-96.
35. Alvarez-Lerma F, Alvarez B, Ruiz F et al. for the ADANN Study Group. Empiric broad-spectrum antibiotic therapy of nosocomial pneumonia in the intensive care unit: a prospective observational study. Crit Care 2006; 10: R78.
36. Kumar A, Roberts D, Wood KE et al. Duration of hypotension prior to initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
37. Gaieski DF, Mikkelsen ME, Band RA et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010; 38: 1045-53.
38. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-55.
39. Shankar-Hari M, Wyncoll D. Utility of an antibiotic guideline in hospital-associated infections. Crit Care 2010; 14: P51.
40. Loeb M, Simor AE, Landry L et al. Adherence to antibiotic guidelines for pneumonia in chronic-care facilities in Ontario. Clin Invest Med 2001; 24: 304-10.
41. Menéndez R, Torres A, Zalacai{dotless}́n R et al. on behalf of the NEUMOFAIL Group. Guidelines for the treatment of community-acquired pneumonia-predictors of adherence and outcome. Am J Respir Crit Care Med 2005; 172: 757-62.
42. Dambrava PG, Torres A, Valles X et al. Adherence to guidelines' empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008; 32: 892-901.
43. Marras TK, Chan CK. Use of guidelines in treating community-acquired pneumonia. Chest 1998; 113: 1689-94.
44. Schwartz DN, Furumoto-Dawson A, Itokazu GS. Preventing mismanagement of community-acquired pneumonia at an urban public hospital: implications for institution-specific practice guidelines. Chest 1998; 113: 194S-8S.
45. Hirani NA, Macfarlane JT. Impact of management guidelines on the outcome of severe community acquired pneumonia. Thorax 1997; 52: 17-21.
46. Mortensen EM, Restrepo M, Anzueto A et al. Effects of guidelineconcordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726-31.
47. Mortensen EM, Restrepo MI, Anzueto A et al. Antibiotic therapy and 48-hour mortality for patients with pneumonia. Am J Med 2006; 119: 859-64.
48. Frei CR, Restrepo MI, Mortensen EM et al. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006; 119: 865-71.
49. Hageman JC, Uyeki TM, Francis JS et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis 2006; 12: 894-9.
50. Pogue M, Burton S, Kreyling P et al. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza-Louisiana and Georgia, December 2006-January 2007. JAMA 2007; 297: 2070-2.
51. Francis JS, Doherty MC, Lopatin U et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-7.
52. Naimi T, LeDell K, Como-Sabetti K et al. Comparison of community and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: 2976-84.
53. Okuma K, Iwakawa K, Turnidge JD et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40: 4289-94.
54. Mandell LA, Wunderink RG, Anzueto A et al. IDSA/ATS guidelines for CAP in adults. Clin Infect Dis 2007; 44: S27-72.
55. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
56. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009; 22: 316-25.
57. Mangi RJ, Greco T, Ryan J et al. Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia. Am J Med 1988; 84: 68-74.
58. Croce MA, Fabian TC, Stewart RM et al. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma 1993; 35: 303-9.
59. Cometta A, Baumgartner JD, Lew D et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38: 1309-13.
60. Rubinstein E, Lode H, Grassi C, and an antibiotic study group. Ceftazidime monotherapy vs. ceftriaxone/tobramycin for serious hospital-acquired Gram-negative infections. Clin Infect Dis 1995; 20: 1217-28.
61. Sieger B, Berman S, Geckler RW et al. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Crit Care Med 1997; 25: 1663-70.
62. Alvarez Lerma F, Serious Infection Study Group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13: 70-81.
63. Damas P, Garweg C, Monchi M et al. Combination therapy versus monotherapy: a randomised pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia. Crit Care 2006; 10: R52.
64. Heyland DK, Dodek P, Muscedere J et al. for the Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008; 36: 737-44.
65. Garnacho-Montero J, Sa-Borges M, Sole-Violan J et al. Optimal management therapy for Pseudomonas aeruginosa ventilator associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med 2007; 25: 1888-95.
66. Paul M, Benuri-Silbiger I, Soares-Weiser K et al. b Lactam monotherapy versus b lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328: 668.
67. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4: 519-27.
68. Furno P, Giampaolol B, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a metaanalysis. Lancet Infect Dis 2002; 2: 231-42.
69. Bochud PY, Glauser M, Calandra T. Antibiotics in sepsis. Int Care Med 2001; 27: S33-48.
70. Vincent JL, Bihari DJ, Suter PM et al. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. JAMA 1995; 274: 639-44.
71. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49: 3640-5.
72. Solomkin JS, Mazuski J. Intra-abdominal sepsis: newer interventional and antimicrobial therapies. Infect Dis Clin North Am 2009; 23: 593-608.
73. Montravers P, Dupont H, Gauzit R et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-52.
74. Eggimann P, Francioli P, Bille J et al. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27: 1066-72.
75. Mean M, Marchetti O, Calandra T. Bench-to-bedside review: Candida infections in the intensive care unit. Crit Care 2008; 12: 204.
76. Pappas PG, Rex JH, Sobel JD et al. Guidelines for the treatment of candidiasis. Clin Infect Dis 2004; 38: 161-89.
77. Hof H. Developments in the epidemiology of invasive fungal infections-implications for the empiric and targeted antifungal therapy. Mycoses 2008; 51: 1-6.
78. Pfaller MA, Boyken L, Hollis RJ et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46: 150-6.
79. Daniels R, Nutbeam T. (eds). The ABC of Sepsis. Chichester: Wiley Blackwell, 2010.
80. Durairaj L, Schmidt GA. Fluid therapy in resuscitated sepsis-less is more. Chest 2008; 133: 252-63.
81. Finfer S, Bellomo R, Boyce N et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004; 350: 2247-56.
82. Choi PTL, Yip G, Quinonez LG et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27: 200-10.
83. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. BMJ 1998; 316: 961-4.
84. Schortgen F, Lacherade JC, Bruneel F et al. Effects of hydroxyethyl starch and gelatine on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911-6.
85. Sakr Y, Payen D, Reinhart K et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 216-24.
86. Brunkhorst FM, Engel C, Bloos F et al. for the German Competence Network Sepsis (SepNet). Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
87. Hü ter L, Simon TP, Weinmann L et al. Hydroxyethylstarch impairs renal function and induces interstitial proliferation, macrophage infiltration and tubular damage in an isolated renal perfusion model. Crit Care 2009; 13: R23.
88. Scandinavian Starch for Severe Sepsis/Septic Shock Trial at www. clinicaltrials.gov.,http://clinicaltrials.gov/ct2/show/NCT00962156 (5 May 2010, date last accessed).
89. Prough DS, Bidani A. Hyperchloremic metabolic acidosis is a predictable consequence of intraoperative infusion of 0.9% saline. Anesthesiology 1999; 90: 1247-9.
90. Kellum JA. Saline-induced hyperchloremic metabolic acidosis. Crit Care Med 2002; 30: 259-61.
91. Gunnerson KJ, Saul M, He S et al. Lactate versus non-lactate metabolic acidosis: a retrospective outcome evaluation of critically ill patients. Crit Care 2006; 10: R22.
92. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.
93. Micek ST, Roubinian N, Heuring T et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34: 2707-13.
94. Jones AE, Focht A, Horton JM. Prospective external validation of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock. Chest 2007; 132: 425-32.
95. Puskarich MA, Marchick M, Kline JA et al. One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study. Crit Care 2009; 13: R167.
96. Ho BC, Bellomo R, McGain F et al. The incidence and outcome of septic shock patients in the absence of early-goal directed therapy. Crit Care 2006; 10: R80.
97. Van Beest P, Hofstra J, Schultz M et al. The incidence of low venous oxygen saturation on admission in the ICU: a multicenter observational study in the Netherlands. Crit Care 2008; 12: R33.
98. The Protocolized Care for Early Septic Shock (ProCESS) study. https://crisma.upmc.com/processtrial/info2.asp (5 May 2010, date last accessed).
99. Peake SL, Bailey M, Bellomo R et al. ARISE Investigators, for the Australian and New Zealand Intensive Care Society Clinical Trials Group. Australasian resuscitation of sepsis evaluation (ARISE): a multi-centre, prospective, inception cohort study. Resuscitation 2009; 80: 811-8.
100. Protocolised Management in Sepsis (ProMISe) Trial information. https://www.icnarc.org/CMS/DisplayContent.aspx?root=RESEARCH (5 January 2011, date last accessed).
101. Jones AE, Shapiro NI, Trzeciak S et al. for the Emergency Medicine Shock Research Network (EMShockNet) Investigators. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy. JAMA 2010; 303: 739-46.
102. Robson WP, Daniels R. The Sepsis Six: helping patients to survive sepsis. Br J Nurs 2008; 17: 16-21.
103. Robson W, Nutbeam T, Daniels R. Sepsis-a need for pre-hospital intervention? Emerg Med J 2009; 26: 535-8.
104. Willson A, Hope D, Smithies M et al. Welsh Critical Care Improvement Programme: the 'how to guide' for improving critical care rapid response to acute illness 2008. http://www.1000livescampaign.wales.nhs.uk (5 May 2010, date last accessed).
105. Daniels R, Nutbeam I, McNamara G et al. The sepsis six and the severe sepsis resuscitation bundle: a prospective observational cohort study. Emerg Med J 2010; doi:10.1136/emj.2010.095067.
106. Pierrakos C, Vincent J-L. Sepsis biomarkers: a review. Critical Care 2010; 14: R15.
107. Tenover FC. Rapid detection and identification of bacterial pathogens using novel molecular technologies: infection control and beyond. Clin Infect Dis 2007; 44: 418-23.
108. Järvinen AK, Laakso S, Piiparinen P et al. Rapid identification of bacterial pathogens using a PCR- and microarray-based assay. BMC Microbiol 2009; 9: 161.
109. Hettwer S, Wilhelm J, Hammer D et al. Sepsis in the emergency department: pathogen identification by blood cultures and PCR. Crit Care 2009; 13: P378.
110. Peterson LR, Dalhoff A. Towards targeted prescribing: will the cure for antimicrobial resistance be specific, directed therapy through improved diagnostic testing? J Antimicrob Chemother 2004; 53: 902-5.
111. Roche Molecular Diagnostics. SeptiFast: the impact of rapid results. http://molecular.roche.com/commonfiles/media/pdf/51_septifast.pdf (10 June 2010, date last accessed).
112. BlackBio SL. BlackLight Sepsis Kit. http://www.blackbio.eu/documents/flyer_blackLight_sepsis_kit.pdf (10 June 2010, date last accessed).
113. Turenne CY, Sanche SE, Hoban DJ et al. Rapid identification of fungi by using the ITS2 genetic region and an automated fluorescent capillary electrophoresis system. J Clin Microbiol 1999; 37: 1846-51.
114. Borman MA, Linton CJ, Miles S-J et al. Molecular identification of pathogenic fungi. J Antimicrob Chemother 2008; 61 Suppl 1: i7-12.
115. Yang RB, Mark MR, Gray A et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature 1998; 395: 284.
116. Ince C. The microcirculation is the motor of sepsis. Crit Care 2005; 9: S13-9.
117. Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004; 4: 729-41.
118. Weber SU, Schewe JC, Lehmann LE et al. Induction of Bim and Bid gene expression during accelerated apoptosis in severe sepsis. Crit Care 2008; 12: R128.
119. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.